Baxter Gets FDA Approval for Myxredlin Insulin

Date : 07/22/2019 @ 2:49PM
Source : Dow Jones News
Stock : Baxter International Inc (BAX)
Quote : 87.2  -0.11 (-0.13%) @ 5:36PM

Baxter Gets FDA Approval for Myxredlin Insulin

Baxter (NYSE:BAX)
Historical Stock Chart

2 Months : From Jun 2019 to Aug 2019

Click Here for more Baxter Charts.

By Chris Wack

 

Baxter International Inc. (BAX) said Monday the U.S. Food and Drug Administration approved Myxredlin insulin for IV infusion.

The medication company said Myxredlin is indicated for use as a short-acting human insulin to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Baxter said it expects Myxredlin to be available in the U.S. before the end of 2019.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

July 22, 2019 09:34 ET (13:34 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest BAX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.